Amount Raised
$40 Million
Round Type
Series C
AuroraHealthcareDescription
Cerebral Therapeutics, a clinical-stage pharmaceutical company pioneering therapies for neurological diseases, announced today $40 million in Series C funding led by Lynx1 Capital Management with participation from existing investors RA Capital Management, Perceptive Advisors, Vivo Capital LLC, and Granite Point Capital Management L.P. In conjunction with the financing round, Weston Nichols, Ph.D., Managing Partner of Lynx1 Capital Management and Tim Scannell, former President and COO of Stryker, will join the Board of Directors.
Who to call at Cerebral Therapeutics, Inc., and when
A new round usually means Cerebral Therapeutics, Inc. is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Cerebral Therapeutics, Inc. raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Cerebral Therapeutics, Inc., from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Cerebral Therapeutics, Inc.. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Cerebral Therapeutics, Inc. raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Cerebral Therapeutics, Inc. raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.